Review



osimertinib hy 15722  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    MedChemExpress osimertinib hy 15722
    A) Schematic of a standardized workflow for high-throughput screening on OC Plex-32 cancer models to measure drug effect B, C) Viability results for chips treated with Gemcitabine, Gefitinib, and <t>Osimertinib</t> for 48 hours B) by CellTiter-Glo ATP assay and C) by imaging assay (n=4). Imaging metrics utilized for dose response curves establishment were selected based on the Z’-factor ranking. The left graph shows the ratio of the area of viable cells to the area of all cells per chip. The right graphs demonstrate the area of viable cells. Data were normalized to the value of the vehicle controls in all graphs in B and C . D) Representative images of chips treated with Osimertinib at 0.01-100 μM for 48 hours and then stained with Hoechst33342 and EthD-2 for viability assessment. The right two image columns are showing the zoomed-in view of the region in the corresponding gray panes in the same row E) Correlation graphs comparing imaging results to CellTiter-Glo result for drug effect evaluation. Each dot represents one chip.
    Osimertinib Hy 15722, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/osimertinib hy 15722/product/MedChemExpress
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    osimertinib hy 15722 - by Bioz Stars, 2024-10
    86/100 stars

    Images

    1) Product Images from "Combining Scalable Organ Chip Platform with Deep Learning-Based Imaging Analysis for Cancer Therapeutic Screening"

    Article Title: Combining Scalable Organ Chip Platform with Deep Learning-Based Imaging Analysis for Cancer Therapeutic Screening

    Journal: bioRxiv

    doi: 10.1101/2024.06.10.598272

    A) Schematic of a standardized workflow for high-throughput screening on OC Plex-32 cancer models to measure drug effect B, C) Viability results for chips treated with Gemcitabine, Gefitinib, and Osimertinib for 48 hours B) by CellTiter-Glo ATP assay and C) by imaging assay (n=4). Imaging metrics utilized for dose response curves establishment were selected based on the Z’-factor ranking. The left graph shows the ratio of the area of viable cells to the area of all cells per chip. The right graphs demonstrate the area of viable cells. Data were normalized to the value of the vehicle controls in all graphs in B and C . D) Representative images of chips treated with Osimertinib at 0.01-100 μM for 48 hours and then stained with Hoechst33342 and EthD-2 for viability assessment. The right two image columns are showing the zoomed-in view of the region in the corresponding gray panes in the same row E) Correlation graphs comparing imaging results to CellTiter-Glo result for drug effect evaluation. Each dot represents one chip.
    Figure Legend Snippet: A) Schematic of a standardized workflow for high-throughput screening on OC Plex-32 cancer models to measure drug effect B, C) Viability results for chips treated with Gemcitabine, Gefitinib, and Osimertinib for 48 hours B) by CellTiter-Glo ATP assay and C) by imaging assay (n=4). Imaging metrics utilized for dose response curves establishment were selected based on the Z’-factor ranking. The left graph shows the ratio of the area of viable cells to the area of all cells per chip. The right graphs demonstrate the area of viable cells. Data were normalized to the value of the vehicle controls in all graphs in B and C . D) Representative images of chips treated with Osimertinib at 0.01-100 μM for 48 hours and then stained with Hoechst33342 and EthD-2 for viability assessment. The right two image columns are showing the zoomed-in view of the region in the corresponding gray panes in the same row E) Correlation graphs comparing imaging results to CellTiter-Glo result for drug effect evaluation. Each dot represents one chip.

    Techniques Used: High Throughput Screening Assay, ATP Assay, Imaging, Staining



    Similar Products

    osimertinib hy 15722  (MedChemExpress)
    86
    MedChemExpress osimertinib hy 15722
    A) Schematic of a standardized workflow for high-throughput screening on OC Plex-32 cancer models to measure drug effect B, C) Viability results for chips treated with Gemcitabine, Gefitinib, and <t>Osimertinib</t> for 48 hours B) by CellTiter-Glo ATP assay and C) by imaging assay (n=4). Imaging metrics utilized for dose response curves establishment were selected based on the Z’-factor ranking. The left graph shows the ratio of the area of viable cells to the area of all cells per chip. The right graphs demonstrate the area of viable cells. Data were normalized to the value of the vehicle controls in all graphs in B and C . D) Representative images of chips treated with Osimertinib at 0.01-100 μM for 48 hours and then stained with Hoechst33342 and EthD-2 for viability assessment. The right two image columns are showing the zoomed-in view of the region in the corresponding gray panes in the same row E) Correlation graphs comparing imaging results to CellTiter-Glo result for drug effect evaluation. Each dot represents one chip.
    Osimertinib Hy 15722, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/osimertinib hy 15722/product/MedChemExpress
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    osimertinib hy 15722 - by Bioz Stars, 2024-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    A) Schematic of a standardized workflow for high-throughput screening on OC Plex-32 cancer models to measure drug effect B, C) Viability results for chips treated with Gemcitabine, Gefitinib, and Osimertinib for 48 hours B) by CellTiter-Glo ATP assay and C) by imaging assay (n=4). Imaging metrics utilized for dose response curves establishment were selected based on the Z’-factor ranking. The left graph shows the ratio of the area of viable cells to the area of all cells per chip. The right graphs demonstrate the area of viable cells. Data were normalized to the value of the vehicle controls in all graphs in B and C . D) Representative images of chips treated with Osimertinib at 0.01-100 μM for 48 hours and then stained with Hoechst33342 and EthD-2 for viability assessment. The right two image columns are showing the zoomed-in view of the region in the corresponding gray panes in the same row E) Correlation graphs comparing imaging results to CellTiter-Glo result for drug effect evaluation. Each dot represents one chip.

    Journal: bioRxiv

    Article Title: Combining Scalable Organ Chip Platform with Deep Learning-Based Imaging Analysis for Cancer Therapeutic Screening

    doi: 10.1101/2024.06.10.598272

    Figure Lengend Snippet: A) Schematic of a standardized workflow for high-throughput screening on OC Plex-32 cancer models to measure drug effect B, C) Viability results for chips treated with Gemcitabine, Gefitinib, and Osimertinib for 48 hours B) by CellTiter-Glo ATP assay and C) by imaging assay (n=4). Imaging metrics utilized for dose response curves establishment were selected based on the Z’-factor ranking. The left graph shows the ratio of the area of viable cells to the area of all cells per chip. The right graphs demonstrate the area of viable cells. Data were normalized to the value of the vehicle controls in all graphs in B and C . D) Representative images of chips treated with Osimertinib at 0.01-100 μM for 48 hours and then stained with Hoechst33342 and EthD-2 for viability assessment. The right two image columns are showing the zoomed-in view of the region in the corresponding gray panes in the same row E) Correlation graphs comparing imaging results to CellTiter-Glo result for drug effect evaluation. Each dot represents one chip.

    Article Snippet: The compounds used in these studies, Gefitinib (Medchem Express, HY-50895), Gemcitabine (MedChem Express, HY-17026), Osimertinib (HY-15722), and Savolitinib (HY-15959), Paclitaxel (HY-B0015), Regorafenib (HY-10331), Pemetrexed (HY-10820) were individually prepared in sterile DMSO as 1000x stocks (0.01, 0.1, 1, 10, 100 mM), aliquoted, and stored at -80 °C.

    Techniques: High Throughput Screening Assay, ATP Assay, Imaging, Staining